DEEP RESEARCH · QURIENT

Qurient (115180): CDK7, ADC Combinations, and Telacebec PRV Value Chain

A structured view of the network R&D model and the Q901-centered oncology pipeline.

Published: 2025-11-29 · Technology and investment analysis · Naver Blog source

Investment decisions are your responsibility. This material is research and is not a recommendation to buy or sell.

0. Bottom line first

Qurient's investment point is whether Q901, also called Mocaciclib, can become a CDK7 inhibitor combination partner in the ADC era, and whether telacebec's PRV can become non-dilutive funding. The source treats DongKoo Bio & Pharma's 2024 strategic investment and management participation as a turning point that reduced financial and governance uncertainty.

Attached audio: Qurient CDK7 Q901 oncology market strategy.mp3

Official fact: Qurient was spun out from Institut Pasteur Korea in 2008. The source identifies partnerships with Max Planck Institute and LDC, Q901 (CDK7 inhibitor), Q702 (Axl/Mer/CSF1R inhibitor), telacebec, and QP101 as core assets.

Interpretation: I view Qurient less as a traditional pharma company and more as a project-manager biotech that converts external basic research into clinical development and business development. Its core capability is network, trial design, and partnering execution rather than lab scale alone.

Qurient Value ChainImporting basic research and focusing on clinical and business development

External institutesIPK, MPI, LDC

Clinical developmentQ901, Q702, telacebec

Global partnersNCI, MSD, Synaffix, TB Alliance

MonetizationLicensing, PRV, non-dilutive funding

The key is how quickly scientific progress converts into enterprise value and cash.

1. Network R&D model

The source says Qurient uses a network R&D model that discovers promising basic research from global institutions and advances it toward commercialization. It is framed as an evolved NRDO model focused on development and business development.

Category	Traditional pharma	Qurient model	Expected effect
Early research	Internal labs and high fixed costs	External institutes such as IPK and MPI	Lower fixed cost and access to new science
Development focus	Vertically integrated from research to commercialization	Clinical development and BD focus	Speed and capital efficiency
Value capture	Product sales or own commercialization	Licensing, partnering, PRV	Potential non-dilutive funding

2. Core pipeline

Q901

CDK7 inhibitor

The source says Q901 is gaining evidence as an ADC combination partner and has credibility through work with NCI and MSD.

Q702

Axl/Mer/CSF1R

A pipeline targeting the tumor microenvironment and immuno-oncology combinations, presented as a niche-market asset.

Telacebec

TB and PRV option

TB Alliance bears late-stage clinical costs. If approved, Qurient may receive and sell a PRV, forming the non-dilutive funding thesis.

QP101

Next growth driver

The source views QP101 as expanding pipeline depth and breadth alongside Q901, telacebec, and Q702.

3. Financial position

Official fact: The source cites approximately KRW 20.5 billion of cumulative operating loss in 3Q 2025, KRW 21.8 billion of CB and BW issuance completed in November 2025, about KRW 16 billion of cash and cash equivalents at the end of September 2025, and an annual KRW 7 billion to 9 billion revenue base from the H Pharm merger.

Interpretation: Qurient remains a loss-making biotech. However, the DongKoo investment, CB/BW financing, and H Pharm revenue base reduce near-term liquidity and listing-maintenance risk. The decision ultimately narrows to Q901 data and the probability of telacebec PRV monetization.

4. Risks

If Q901 Phase 2 does not show statistically meaningful efficacy such as PFS or ORR, enterprise value could be hit hard.
Telacebec development speed depends on TB Alliance decisions.
CBs, BWs, and preferred shares can create dilution risk.
PRV sale proceeds are a possibility, not confirmed cash.

5. Catalysts

Q901 RP2D confirmation and early efficacy data.
Keytruda combination data showing whether immunotherapy response improves.
Progress in telacebec Australian registrational trial, NDA timeline, and PRV visibility.
Licensing of Q901 or QP101 to a global big pharma partner.

6. My conclusion

The source's phrase that Qurient is crossing the threshold where scientific output becomes intrinsic company value fits the story. But the company still has to cross that threshold with data and contracts. I would track Q901 clinical data, telacebec PRV timing, dilution management, and management stability after DongKoo's involvement.

Sources

Naver original